| Autor: |
Counts, G. W., Hill, C. D., Hooton, T. M., Turck, M. |
| Zdroj: |
Journal of Antimicrobial Chemotherapy (JAC); 1982, Vol. 10 Issue suppl_C, p201-207, 7p |
| Abstrakt: |
Ceftizoxime is a new semisynthetic β-lactamase-resistant parenteral cephalosporin. For most Gram-negative bacilli 1.0 mg/l or less of ceftizoxime inhibited 90% of isolates of Gram-negative and Gram-positive bacteria tested by agar dilution. The drug was slightly less active in broth dilution testing, and an inoculum effect was noted in that MIC and MBC were at least two-fold higher when a larger inoculum was employed. Good activity was shown against multi-drug resistant isolates of Serratia marcescens. Ceftizoxime had little activity against isolates of enterococcus and Pseudomonas aeruginosa. In doses of 0.5–1.0 g every 12 h the drug was used to treat pneumonia (71), skin and soft tissue (44), and other infections (5) in hospitalized adult patients. Overall cure rate was 94% (113/120). Sixty-eight of 71 patients with pneumonia and 40 of 44 patients with skin and soft tissue infections had satisfactory clinical and bacteriological responses. Four of six patients with serious infections caused by Ser. marcescens, including four instances of bacteraemia, were successfully treated with ceftizox. The drug was well tolerated, and adverse reactions were few. Transient mild abnormalities of liver function tests were noted in 20% of patients. Thrombocytosis was noted in 38% of 53 patients. No untoward consequences were seen in any of these patients, and abnormal values returned to normal after cessation of therapy. Ceftizoxime is a promising new cephalosporin which might be especially useful in the treatment of infections by Serratia. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
